Auron

Auron Strengthens Board of Directors and Leadership Team with Industry Veterans, Victoria Richon, Ph.D. and Christopher Guiffre, J.D., MBA

Retrieved on: 
Thursday, August 10, 2023
University, University of Nebraska Medical Center, Doctor of Philosophy, Nebraska Medicine, Babson College, MBA, Carroll School of Management, Cubist Pharmaceuticals, Boston College Law School, Pear, Ribon, Cell biology, Memorial, Merck, FDA, Therapy, Management, Auron, Biochemistry, Cerulean, Chemistry, Sanofi

Victoria Richon, Ph.D., was appointed to the company’s board of directors.

Key Points: 
  • Victoria Richon, Ph.D., was appointed to the company’s board of directors.
  • Christopher Guiffre, J.D., MBA, was appointed president and chief operating officer.
  • “We are thrilled to welcome Vicky and Chris to the Auron team during this exciting time for the company,” said Kate Yen, Ph.D., founder and chief executive officer of Auron.
  • Christopher Guiffre, J.D., MBA, joins Auron from Pear Therapeutics where he served as chief financial officer and chief operating officer since 2017.

Auron Therapeutics announces $48 million Series A financing to drive novel oncology pipeline leveraging a machine learning, multi-omics-based platform

Retrieved on: 
Wednesday, July 20, 2022
Neoplasm, GLOBE, Norwest Venture Partners, Polaris Partners, CEO, Research, Drug discovery, UCLA, Therapy, Board, Cancer, American Cancer Society, Machine learning, Eli Lilly and Company, Company, Patient, Growth, Pharmaceutical industry, Vaccine, Auron

Proceeds will be used to advance the lead program toward clinical development and drive additional programs into drug discovery.

Key Points: 
  • Proceeds will be used to advance the lead program toward clinical development and drive additional programs into drug discovery.
  • Dr. Eric Shiozaki, Ph.D., Partner at DCVC Bio and Dr. Alexandra Cantley, Ph.D., Partner at Polaris Partners will be joining the Companys Board of Directors.
  • Dysregulation of normal cellular differentiation processes can alter normal cell biology leading to tumor formation and progression, said Dr.
  • Auron Therapeutics is shifting the paradigm of cancer treatment to target key drivers of dysregulated differentiation and cellular plasticity in tumors.